AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A compound represented by general formula (I):



(I)

a prodrug thereof, or a pharmaceutically acceptable salt thereof,

wherein

R^1 is a hydrogen atom or a lower alkyl group;

R^2 is:

a) a lower alkyl group,

b) a halo-lower alkyl group,

c) a hydroxy-lower alkyl group,

d) a cycloalkyl group,

e) an aryl-cycloalkyl group,

f) a heterocycloalkyl group,

g) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

h) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

i) an aryl-alkenyl group, wherein the ring of the aryl-alkenyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

j) a lower alkyl group substituted with a group selected from a lower alkoxy group or a lower acyloxy group,

k) an aryloxy-lower alkyl group, wherein the ring of the aryloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

l) an aralkyloxy-lower alkyl group, wherein the ring of the aralkyloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

m) an arylsulfanyl-lower alkyl group, wherein the ring of the arylsulfanyl-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

n) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of X^6, X^7 and X^8, or

o) a heteroaryl-lower alkyl group, wherein the ring of the heteroaryl-lower alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of X^6, X^7 and X^8;

X^1, X^2, X^3, X^4 and X^5 are each independently:

a) a halogen atom,

b) a lower alkyl group,

c) a halo-lower alkyl group,

d) a cycloalkyl group,

e) a lower alkoxy group,

f) a halo-lower alkoxy group,

g) a cycloalkyloxy group,

h) a heterocycloalkyloxy group,

i) a lower alkoxy-lower alkoxy group,

j) a hydroxy-lower alkyl group,

k) a hydroxyl group,

l) a carboxy group,

m) a lower alkoxycarbonyl group,

n) an aralkyloxycarbonyl group,

o) a lower acyl group,

p) a cyano group,

q) $-A^1-NR^{20}R^{21}$,

r) $-A^2-SR^{22}$,

s) $-SO_2NR^{23}R^{24}$,

t) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

u) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

v) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

w) a heteroaryloxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or

x) a lower alkoxy group substituted with a group selected form an aryl group or a heteroaryl group, or

when two of X^1, X^2, X^3, X^4 and X^5 are adjacent each other, they are bonded together to form a group represented by $–O-(CH_2)_m-O-$, $-O-(CH_2)_n-$ or $–(CH_2)_p-$;

R^{20} and R^{21} are each independently a hydrogen atom, a lower alkyl group, a cycloalkyl group, a heterocycloalkyl group, a bridged cyclic hydrocarbon group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, a lower acyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group or a di(lower alkyl)amino-lower alkyl group, or

R^{20} and R^{21}, taken together with the nitrogen atom to which they are bonded, form a cyclic amino group, wherein the cyclic amino group is unsubstituted or substituted with one or two substituents selected independently from the group consisting of:

a) a lower alky group,

b) a cycloalkyl group,

c) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group, or adjacent ring-carbon atoms of the aralkyl group are substituted with $–O-(CH_2)_m-O-$,

e) a heteroaryl group,

f) a heteroaryl-lower alkyl group,

g) a lower alkyl group substituted with a group selected from a hydroxyl group, a lower alkoxy group, a carboxy group, an aralkyloxycarbonyl group, a cyclic aminocarbonyl group or a di(lower alkyl)amino group,

h) a hydroxyl group,

i) an oxo group,

j) a lower alkoxycarbonyl group,

k) an aralkyloxycarbonyl group,

l) a carbamoyl group,

m) a lower acyl group,

n) a benzoyl group,

o) a di(lower alkyl)amino group, and

p) a diphenylmethylene group;

A^1 is a bond, a C_{1-3}-alkylene group or a carbonyl group;

A^2 is a bond or a C_{1-3}-alkylene group;

R^{22} is:

a) a lower alkyl group,

b) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

c) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group, or

d) a di(lower alkyl)amino-lower alkyl group;

R^{23} and R^{24} are each independently a hydrogen atom or a lower alkyl group, or

R^{23} and R^{24}, taken together with the nitrogen atom to which they are bonded, form a cyclic amino group, wherein the cyclic amino group is unsubstituted or substituted with a group selected from a lower alkyl group or an aralkyl group;

m is 1 or 2;

n is 2 or 3;

p is 3 or 4;

X^6, X^7 and X^8 are each independently:

a) a halogen atom,

b) a lower alkyl group,

c) a halo-lower alkyl group,

d) a hydroxy-lower alkyl group,

e) a cycloalkyl group,

f) a heterocycloalkyl-lower alkyl group,

g) a lower alkoxy group,

h) a halo-lower alkoxy group,

i) a lower acyl group,

j) a carboxy group,

k) $-A^1\text{-}NR^{20}R^{21}$,

l) $-A^2\text{-}SR^{22}$,

m) $-SO_2NR^{23}R^{24}$,

n) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

o) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

p) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower

alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

q) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

r) a heteroaryloxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or

s) an aralkyloxy group;

R^3, R^4, R^5 and R^6 are each independently:

a) a hydrogen atom,

b) a halogen atom,

c) a lower alkyl group,

d) a halo-lower alkyl group,

e) a lower alkoxy group,

f) a halo-lower alkoxy group,

g) a hydroxyl group,

h) a cyano group,

i) an aryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

j) an aralkyloxy group, wherein the ring of the aralkyloxy group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

k) a di(lower alkyl)amino group,

l) a lower alkylsulfanyl group, or

m) a nitro group, or

when two of R^3, R^4, R^5 and R^6 are adjacent each other, they are bonded together to form a group represented by –CH=CH-CH=CH-, provided that at least one of R^3, R^4, R^5 and R^6 is other than a hydrogen atom;

with the proviso that the following compounds are excluded:

(1) 1-acetylaminonaphtho[2,1-b]furan-2-carboxamide,

(2) 1-benzoylaminonaphtho[2,1-b]furan-2-carboxamide,

(3) 3-benzoylamino-5-chlorobenzofuran-2-carboxamide,

(4) 5-chloro-3-[2-(3,4-diethoxyphenyl)acetylamino]-benzofuran-2-carboxamide,

(5) 5-bromo-3-[2-(3,4-diethoxyphenyl)acetylamino]-benzofuran-2-carboxamide,

(6) 5-chloro-3-(2-chloroacetylamino)benzofuran-2-

carboxamide, and

(7) 3-acetylamino-5-chlorobenzofuran-2-carboxamide.

2. (original): The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a hydrogen atom.

3. (original): The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R^3 is a hydrogen atom.

4. (original): The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein

R^2 is:

a) a lower alkyl group,

b) a cycloalkyl group,

c) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

e) a lower alkoxy-lower alkyl group,

f) an aryloxy-lower alkyl group, wherein the ring of the aryloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5,

g) an aralkyloxy-lower alkyl group, wherein the ring of the aralkyloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5, or

h) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of X^6, X^7 and X^8; and

X^1, X^2, X^3, X^4, X^5, X^6, X^7 and X^8 are as defined in claim 1.

5. (original): The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R^4, R^5 and R^6 are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group or a lower alkoxy group, provided that at least one of R^4, R^5 and R^6 is other than a hydrogen atom.

6. (original): The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

R^2 is:

a) a cycloalkyl group,

b) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of X^1, X^2, X^3, X^4 and X^5, or

c) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of X^6, X^7 and X^8.

7. (original): The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein

X^1, X^2, X^3, X^4 and X^5 are each independently:

a) a halogen atom,

b) a lower alkyl group,

c) a lower alkoxy group,

d) a halo-lower alkoxy group,

e) a heterocycloalkyloxy group,

f) a hydroxyl group,

g) $-A^1\text{-}NR^{20}R^{21}$,

h) $-A^2\text{-}SR^{22}$,

i) $-SO_2NR^{23}R^{24}$,

j) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and di(lower alkyl)amino-lower alkyl group, or

when two of X^1, X^2, X^3, X^4 and X^5 are adjacent each other, they are bonded together to form $-OCH_2O-$; and

X^6, X^7 and X^8 are each independently:

a) a halogen atom,

b) a lower alkyl group,

c) a hydroxy-lower alkyl group,

d) a cycloalkyl group,

e) a heterocycloalkyl-lower alkyl group,

f) $-A^1-NR^{20}R^{21}$,

g) $-SO_2NR^{23}R^{24}$,

h) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or

i) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group; and

A^1, A^2, R^{20}, R^{21}, R^{22}, R^{23} and R^{24} are as defined in claim 1.

8. (original): The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

(1) 3-cyclopropanecarbonylamino-5-fluorobenzofuran-2-carboxamide;

(2) 5-chloro-3-cyclopropanecarbonylaminobenzofuran-2-carboxamide;

(3) 3-(3-fluorobenzoylamino)-6-methoxybenzofuran-2-carboxamide;

(4) 3-(4-fluorobenzoylamino)-6-methoxybenzofuran-2-

carboxamide;

(5) 5-fluoro-3-(3-methylbenzoylamino)benzofuran-2-carboxamide;

(6) 3-(benzo[1,3]dioxole-5-carbonyl)amino-6-fluoro-benzofuran-2-carboxamide;

(7) 5-chloro-3-(furan-2-carbonyl)aminobenzofuran-2-carboxamide;

(8) 5,7-difluoro-3-(furan-2-carbonyl)aminobenzofuran-2-carboxamide;

(9) 5,7-difluoro-3-(5-methylfuran-2-carbonyl)amino-benzofuran-2-carboxamide;

(10) 3-(5-ethylfuran-2-carbonyl)amino-5-fluorobenzofuran-2-carboxamide;

(11) 3-(5-ethylfuran-2-carbonyl)amino-5,7-difluoro-benzofuran-2-carboxamide;

(12) 6-methoxy-3-(5-phenylfuran-2-carbonyl)aminobenzofuran-2-carboxamide;

(13) 6-fluoro-3-(6-phenoxypyridine-3-carbonyl)amino-benzofuran-2-carboxamide;

(14) 6-methoxy-3-(2-methoxyacetylamino)benzofuran-2-carboxamide;

(15) 3-[2-(4-chlorophenoxy)acetylamino]-5-fluorobenzofuran-

2-carboxamide;

(16) 3-(2-benzyloxyacetylamino)-5-fluorobenzofuran-2-carboxamide;

(17) 6-chloro-3-cyclopropanecarbonylaminobenzofuran-2-carboxamide;

(18) 3-cyclopropanecarbonylamino-5,7-difuorobenzofuran-2-carboxamide;

(19) 7-chloro-3-cyclopropanecarbonylamino-5-fluoro-benzofuran-2-carboxamide;

(20) 3-cyclopropanecarbonylamino-5-fluoro-7-methoxy-benzofuran-2-carboxamide;

(21) 3-cyclobutanecarbonylamino-5,7-difluorobenzofuran-2-carboxamide;

(22) 5-fluoro-7-methoxy-3-(4-methoxybenzoylamino)-benzofuran-2-carboxamide;

(23) 5,7-difluoro-3-phenylacetylaminobenzofuran-2-carboxamide;

(24) 5,7-difluoro-3-[3-(4-methylpiperazine-1-carbonyl)-benzoylamino]benzofuran-2-carboxamide;

(25) 6-methoxy-3-[3-(4-phenylpiperazin-1-ylmethyl)benzoyl-amino]benzofuran-2-carboxamide;

(26) 6-methoxy-3-[4-(1-methyl-1H-imidazol-2-ylsulfanyl-

methyl)benzoylamino]benzofuran-2-carboxamide;

(27) 3-[5-(4-benzylpiperazin-1-ylmethyl)furan-2-carbonyl]-amino-5,7-difluorobenzofuran-2-carboxamide;

(28) 3-[5-(4-benzo[1,3]dioxol-5-ylmethylpiperazin-1-ylmethyl)furan-2-carbonyl]amino-5,7-difluorobenzofuran-2-carboxamide;

(29) tert-butyl 4-[5-(2-carbamoyl-5,7-difluorobenzofuran-3-ylcarbamoyl)furan-2-ylmethyl]piperazine-1-carboxylate, and

(30) 5-fluoro-3-[5-(1-hydroxyethyl)furan-2-carbonyl]amino-benzofuran-2-carboxamide.

9. (currently amended): A pharmaceutical composition which comprises, as an active ingredient, a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof.

10. (currently amended): A therapeutic or prophylactic agent for a disease mediated by adenosine A_{2A} receptors, which comprises, as an active ingredient, a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof.

11. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A_{2A} receptors is a motor function disorder.

12. (original): The therapeutic or prophylactic agent according to claim 11, wherein the motor function disorder is Parkinson's disease, Huntington's disease or Wilson's disease.

13. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A_{2A} receptors is depression or an anxiety disorder.

14. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A_{2A} receptors is a cognitive function disorder.

15. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A_{2A} receptors is a cerebral ischemia disorder.

16. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A_{2A} receptors is restless legs syndrome.

17. (currently amended): A pharmaceutical combination comprising a compound according to ~~any one of claims 1 to 8~~ claim 1or a pharmaceutically acceptable salt thereof and at least one selected from anti-Parkinson drugs, antidepressants, drugs for cognitive function disorders and drugs for cerebral ischemia disorders other than adenosine A_{2A} receptor antagonists.

18. (currently amended): A use of a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a disease mediated by adenosine A_{2A} receptors.

19. (currently amended): A method for treating or preventing a disease mediated by adenosine A_{2A} receptors, which comprises administering an effective amount of a compound according to ~~any one of claims 1 to 8~~ claim 1or a pharmaceutically acceptable salt thereof.